RAN-LABEL
  • RAN-BUPROPION XL is transitioning to TARO-BUPROPION XL; product with the new TARO label will be available early in 2020. For this product the DINs, UPCs, markings and formulations will remain the same, only the prefix will change. click here

  • RAN-CEFPROZIL is transitioning to TARO-CEFPROZIL; product with the new TARO label will be available early in 2020. For this product the DINs, UPCs, markings and formulations will remain the same, only the prefix will change. click here

  • RAN-RAMIPRIL HCTZ is transitioning to TARO-RAMIPRIL HCTZ; product with the new TARO label will be available early in 2020. For this product the DINs, UPCs, markings and formulations will remain the same, only the prefix will change click here

  • RAN-ATORVASTATIN is transitioning to TARO-ATORVASTATIN; product with the new TARO label will be available early in 2020. For this product the DINs, UPCs, markings and formulations will remain the same, only the prefix will change. click here

  • RAN-CEFPROZIL ORAL SUSPENSION is transitioning to TARO-CEFPROZIL ORAL SUSPENSION; product with the new TARO label will be available early in 2020. For this product the DINs, UPCs and formulations will remain the same, only the prefix will change. click here

  • RAN-ROSUVASTATIN is transitioning to TARO-ROSUVASTATIN; product with the new TARO label will be available early in 2020. For this product the DINs will remain the same, however, the tablet formulation and appearance will change. Bottles of 90 will be replaced with bottles of 100 and UPCs will change. click here

  • RAN-SOLIFENACIN is transitioning to TARO-SOLIFENACIN; product with the new TARO label will be available early in 2020. For this product the DINs, UPCs, markings and formulations will remain the same, only the prefix will change. click here